JP7695229B2 - Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法 - Google Patents

Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法 Download PDF

Info

Publication number
JP7695229B2
JP7695229B2 JP2022503439A JP2022503439A JP7695229B2 JP 7695229 B2 JP7695229 B2 JP 7695229B2 JP 2022503439 A JP2022503439 A JP 2022503439A JP 2022503439 A JP2022503439 A JP 2022503439A JP 7695229 B2 JP7695229 B2 JP 7695229B2
Authority
JP
Japan
Prior art keywords
compound
mmol
mixture
room temperature
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541545A (ja
JP2022541545A5 (enExample
Inventor
シン チアン
クリストファー エフ． ベンダー
ハ ドゥー
ハイチョウ サン
メリアン ヴィスニック
Original Assignee
リアタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リアタ ファーマシューティカルズ インコーポレイテッド filed Critical リアタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2022541545A publication Critical patent/JP2022541545A/ja
Publication of JP2022541545A5 publication Critical patent/JP2022541545A5/ja
Priority to JP2025094850A priority Critical patent/JP2025131767A/ja
Application granted granted Critical
Publication of JP7695229B2 publication Critical patent/JP7695229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0063—Nitrogen and oxygen at position 2(3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
JP2022503439A 2019-07-19 2020-07-20 Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法 Active JP7695229B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094850A JP2025131767A (ja) 2019-07-19 2025-06-06 Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876467P 2019-07-19 2019-07-19
US62/876,467 2019-07-19
US201962952048P 2019-12-20 2019-12-20
US62/952,048 2019-12-20
PCT/US2020/042788 WO2021016191A1 (en) 2019-07-19 2020-07-20 C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094850A Division JP2025131767A (ja) 2019-07-19 2025-06-06 Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2022541545A JP2022541545A (ja) 2022-09-26
JP2022541545A5 JP2022541545A5 (enExample) 2023-07-27
JP7695229B2 true JP7695229B2 (ja) 2025-06-18

Family

ID=74192606

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022503439A Active JP7695229B2 (ja) 2019-07-19 2020-07-20 Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法
JP2025094850A Pending JP2025131767A (ja) 2019-07-19 2025-06-06 Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025094850A Pending JP2025131767A (ja) 2019-07-19 2025-06-06 Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法

Country Status (10)

Country Link
US (2) US12344631B2 (enExample)
EP (1) EP3999522B1 (enExample)
JP (2) JP7695229B2 (enExample)
KR (1) KR102891865B1 (enExample)
CN (2) CN120248001A (enExample)
AU (1) AU2020316351A1 (enExample)
CA (2) CA3144603C (enExample)
MX (2) MX2022000781A (enExample)
TW (1) TWI861163B (enExample)
WO (1) WO2021016191A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
KR102891865B1 (ko) * 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
CN120349366A (zh) * 2025-03-07 2025-07-22 国科大杭州高等研究院 五环三萜类衍生物、制备方法及其医药用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125488A1 (en) 2011-03-11 2012-09-20 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2014040056A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
WO2015027206A1 (en) 2013-08-23 2015-02-26 Reata Pharmaceuticals, Inc. Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof
WO2017053868A1 (en) 2015-09-23 2017-03-30 Reata Pharmaceutical, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
WO2021016191A1 (en) 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
DE19817262A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6365768B1 (en) 1999-05-14 2002-04-02 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
JP2004509972A (ja) 2000-09-29 2004-04-02 リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ 酵母に対する殺真菌活性を有するトリテルペン
EP1395255A4 (en) 2000-11-28 2007-09-12 Univ Texas CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
MXPA04006953A (es) 2002-01-18 2005-06-20 Univ Minnesota Sales cuaternarias de triperpeno como surfactantes biologicamente activos.
AU2003303128A1 (en) 2002-05-13 2004-08-13 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
CA2579231C (en) 2004-09-07 2018-07-10 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
EP2032594B1 (en) 2006-06-27 2015-09-23 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
DK2653873T3 (da) 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
HUE043175T2 (hu) 2008-01-11 2019-08-28 Reata Pharmaceuticals Inc Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
SMT202000086T1 (it) 2010-04-12 2020-03-13 Reata Pharmaceuticals Inc Bardoxolone metile per il trattamento dell'obesità
US8618125B2 (en) 2011-01-14 2013-12-31 Heptiva LLC Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
JP6001560B2 (ja) 2011-01-31 2016-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド
DK3444261T3 (da) 2012-04-27 2021-03-08 Reata Pharmaceuticals Inc 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es) 2012-09-10 2015-11-09 Abbvie Inc Derivados de acido glicirretinico y metodos de uso de los mismos.
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125488A1 (en) 2011-03-11 2012-09-20 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
WO2014040056A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2015027206A1 (en) 2013-08-23 2015-02-26 Reata Pharmaceuticals, Inc. Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof
WO2017053868A1 (en) 2015-09-23 2017-03-30 Reata Pharmaceutical, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
WO2021016191A1 (en) 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof

Also Published As

Publication number Publication date
CA3144603A1 (en) 2021-01-28
US12344631B2 (en) 2025-07-01
MX2025007184A (es) 2025-07-01
TWI861163B (zh) 2024-11-11
MX2022000781A (es) 2022-04-26
JP2025131767A (ja) 2025-09-09
US20210040142A1 (en) 2021-02-11
EP3999522B1 (en) 2025-09-03
CN114641483A (zh) 2022-06-17
CN114641483B (zh) 2024-12-06
US20250361263A1 (en) 2025-11-27
CA3249188A1 (en) 2025-06-05
AU2020316351A1 (en) 2022-02-17
CN120248001A (zh) 2025-07-04
TW202116327A (zh) 2021-05-01
CA3144603C (en) 2025-10-21
EP3999522A1 (en) 2022-05-25
WO2021016191A1 (en) 2021-01-28
KR102891865B1 (ko) 2025-11-26
KR20220044942A (ko) 2022-04-12
JP2022541545A (ja) 2022-09-26

Similar Documents

Publication Publication Date Title
JP2025131767A (ja) Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法
JP6129084B2 (ja) Ｃ４−モノメチルトリテルペノイド誘導体およびその使用方法
CN104955833B (zh) 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法
CA2974726C (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
CN115087660A (zh) 在c-17处具有基于氮的取代基的合成三萜类化合物及其使用方法
JP2024504637A (ja) 合成ウルソール酸誘導体及びその使用方法
HK40073498B (zh) C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
HK40073498A (en) C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
HK40080975A (en) Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
HK40101927A (zh) 合成的熊果酸衍生物和其使用方法
EA049347B1 (ru) Синтетические тритерпеноиды с заместителями на основе азота у атома c-17 и способы их применения
HK1247609A1 (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230719

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

R150 Certificate of patent or registration of utility model

Ref document number: 7695229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150